BAF60c and abdominal aortic aneurysm
BAF60c 和腹主动脉瘤
基本信息
- 批准号:10474527
- 负责人:
- 金额:$ 54.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AbdomenAbdominal Aortic AneurysmAddressAffectAgeAneurysmAngiotensin IIAortaApoptosisAtherosclerosisAttentionAttenuatedAutomobile DrivingBlood VesselsCardiovascular systemCatalytic DomainCathepsinsCellsCellular biologyChIP-seqChromatinChromatin Remodeling FactorChromatin StructureCo-ImmunoprecipitationsComplementComplexContractile ProteinsDNADataDevelopmentDiabetes MellitusElastasesElderlyEnergy MetabolismEnvironmentEpigenetic ProcessExtracellular Matrix DegradationFamilyFamily memberFunctional disorderGene ExpressionGenesHeartHomeostasisHumanHyperlipidemiaHypertensionIn VitroIncidenceIndividualInflammationInflammatoryKnock-in MouseKnock-outKnockout MiceLigandsLinkLipidsLoxP-flanked alleleMMP9 geneMedialMediatingMedicalMetabolicMolecularMusOperative Surgical ProceduresOutcomePathogenesisPathologicPathologyPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPhenotypePlayPrevalencePrimary PreventionProcessPromoter RegionsReceptor SignalingRegulationReportingRisk FactorsRoleRuptureSMARCA4 geneSamplingSchemeSex DifferencesSmokingSmooth Muscle MyocytesStainsStimulusSucroseTherapeuticThoracic Aortic AneurysmTissue SampleTissuesTransducersTransgenic MiceTranslatingVascular Smooth MuscleViral VectorWorkbasebrahmachromatin remodelingdifferential expressiongenetic associationgenomic locusgranulocytehigh riskin vivoin vivo Modelinsightknock-downloss of functionmalemembermortalitymortality riskmouse modelnovelnovel therapeuticsp65preventpromoterprotein expressionrecruitrepairedresponsesextherapeutic targettranscription factortranscriptome sequencingvascular inflammation
项目摘要
PROJECT SUMMARY/ABSTRACT
Abdominal Aortic Aneurysm (AAA) is a primary medical concern due to the increasing prevalence and high
mortality rate upon rupture. Although vascular inflammation, extracellular matrix (ECM) degradation, and
subsequent vascular smooth muscle cells (VSMCs) apoptosis are pathologic features and drivers of AAA,
efforts to manipulate these processes did not yet result in any effective drug therapies beyond primary
prevention, creating an urgent need for new drug-based therapeutic strategies. This will be facilitated by a
deeper and comprehensive understanding of the molecular and cellular mechanisms driving onset,
progression, and outcomes of AAA. Chromatin remodeling altering gene expression has been linked to most
pathophysiologic conditions, including atherosclerosis and diabetes, but its role in AAA remains largely
unknown. The BAF60 family comprises three mutually exclusive subunits of the SWItch/Sucrose Non-
Fermentable (SWI/SNF) chromatin remodeling complex. Of relevance to the cardiovascular field, they play
essential roles in controlling lipid homeostasis, energy metabolism (BAF60a), granulocyte (BAF60b) and heart
(BAF60c) development. We found that BAF60a, b and c are differentially expressed in human and mouse AAA
tissues, suggesting a potential role of the BAF60 subunits in VSMC biology and the development of AAA. We
recently reported that loss of BAF60a in VSMCs prevents experimental AAA by reducing vascular inflammation
and ECM degradation in mice. Remarkably, BAF60c is the most abundant BAF60 subunit expressed in VSMC.
Our preliminary data show that BAF60c is downregulated in the abdominal aortic aneurysmal tissue in both
humans and mice. VSMC BAF60c knockout significantly aggravates elastase-induced AAA, and knockdown of
BAF60c in human aortic smooth muscle cells reduced the SMC contractile protein expression and increased
inflammatory genes and MMP9 expression. We hypothesize that VSMC-specific BAF60c attenuates AAA
development by maintaining the VSMC contractile phenotype, and inhibiting vascular inflammation and ECM
degradation. Using gain- and loss-of-function in HASMCs in vitro, AAA-relevant stimuli, our unique VSMC-
specific BAF60c knockout and transgenic mice, two established murine AAA models in vivo, and an integrated
workflow, we will (Aim 1) Demonstrate that VSMC-specific BAF60c attenuates AAA formation with attention to
altered cellular profiles and intercellular cross-talk by scRNAseq and provide proof-of-concept for therapeutic
targeting and (Aim 2) Determine the protective mechanisms of BAF60c in VSMC homeostasis in vitro using
relevant stimuli and RNAseq, ChIP-seq and co-immunoprecipitation. This work will provide unique mechanistic
insights on how various and varying risk factors translate into VSMC dysfunction leading to AAA and provide
the basis for developing novel therapies for AAA.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jifeng Zhang其他文献
Jifeng Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jifeng Zhang', 18)}}的其他基金
Novel methods to improve nuclease mediated homologous recombination, Administrative suppl
改进核酸酶介导的同源重组的新方法,行政补充
- 批准号:
10640401 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:
Kruppel-like factor 11 (KLF11) and atherosclerosis
Kruppel 样因子 11 (KLF11) 和动脉粥样硬化
- 批准号:
9924279 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改善核酸酶介导的同源重组的新方法
- 批准号:
10615626 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改进核酸酶介导的同源重组的新方法
- 批准号:
9345608 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改善核酸酶介导的同源重组的新方法
- 批准号:
10383251 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
相似海外基金
Establishment of human abdominal aortic aneurysm wall strength prediction model using Ex Vivo Superparamagnetic Iron Oxide–Enhanced Magnetic Resonance Imaging
利用Ex Vivo超顺磁性氧化铁建立人体腹主动脉瘤壁强度预测模型
- 批准号:
23K08226 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Vascular smooth muscle cell ferroptosis and abdominal aortic aneurysm
血管平滑肌细胞铁死亡与腹主动脉瘤
- 批准号:
10733477 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Extracellular Vesicle Delivery System for Treatment of Abdominal Aortic Aneurysm
细胞外囊泡递送系统治疗腹主动脉瘤
- 批准号:
10751123 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
I-Corps: A Clinical Decision Support Tool to Manage Abdominal Aortic Aneurysm Patients
I-Corps:管理腹主动脉瘤患者的临床决策支持工具
- 批准号:
2318665 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Standard Grant
Atherosclerosis drives arterial damage and abdominal aortic aneurysm formation and rupture
动脉粥样硬化导致动脉损伤和腹主动脉瘤形成和破裂
- 批准号:
483212 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Operating Grants
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm
开发基于磷脂的纳米疗法治疗腹主动脉瘤
- 批准号:
10749980 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Impact of PCSK9 inhibition on abdominal aortic aneurysm pathobiology and growth
PCSK9 抑制对腹主动脉瘤病理学和生长的影响
- 批准号:
10566800 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
The Role of Amino Acid Starvation Response Kinase GCN2 in Abdominal Aortic Aneurysm
氨基酸饥饿反应激酶 GCN2 在腹主动脉瘤中的作用
- 批准号:
10584543 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:
Atherosclerotic process drives arterial damage, abdominal aortic aneurysm formation, and rupture
动脉粥样硬化过程导致动脉损伤、腹主动脉瘤形成和破裂
- 批准号:
477264 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:
Operating Grants
Endovascular Orifice Detection (EOrD) Device for in situ Fenestration of Abdominal Aortic Aneurysm
用于腹主动脉瘤原位开窗的血管内孔口检测 (EOrD) 装置
- 批准号:
10453104 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:














{{item.name}}会员




